期刊文献+

沙利度胺联合DVD方案治疗多发性骨髓瘤的疗效观察 被引量:1

原文传递
导出
摘要 目的分析沙利度胺联合DVD方案(T—DVD)治疗多发性骨髓瘤(MM)的临床疗效。方法观察组25例初治MM患者予以T—DVD方案(T—DVD组),28d为1个疗程,共4个疗程。沙利度胺起始剂量为100mg/d,每周增加50mg/d,最大剂量为200mg/d,持续12周以上。对照组22例初治MM患者予以T—VAD方案(T—VAD组),28d为1个疗程,共4个疗程。4个疗程结束后判定疗效,比较不良反应发生情况。结果T—DVD组完全缓解(CR)8例,部分缓解(PR)8例,进步(I)5例,无效(NR)4例;T—VAD组CR7例,PR8例,I2例,NR5例(其中1例肾衰竭死亡,1例合并败血症死亡),两组总有效率分别为80.00%(20/25)、77.27%(17/22),差异无统计学意义(X2=0.342,P〉0.05)。两组不良反应发生率[32%(8/25)与68%(15/22)]比较,差异有统计学意义(x2=6.131,P〈0.05)。结论T.DVD方案治疗MM患者有效率高、安全性好。
出处 《白血病.淋巴瘤》 CAS 2013年第8期495-497,共3页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献6

二级参考文献42

  • 1Blade J, Samson D, Reeee D, et al. Cri- teria for evaluating disease response and progression in patients with multiple my- eloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant [J]. Br J Haematol, 1998,102 (5):1115-1123.
  • 2Zervas K, Mihou D, Katodritou E, et al.VAD-doxil versus VAD-doxil plus thal- idomide as initial treatment for multiple myeloma: results ofa multicenter randomi- ,zed trial of the Greek Myeloma Study Group [J]. Ann Oncol, 2007,18(8):1369- 1375.
  • 3Chanan-Khan AA, Lee K. Pegylated lipo- somal doxorubicin and immunomodul- atory drug combinations in multiple myel- oma: rationale and clinical experience [J]. Clin Lymphoma Myeloma, 2007,7(Suppl 4):$163-169.
  • 4Baz R, Walker E, Karam MA, et al.Len- alidomide and pegylated liposomal dox- orubicin based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy [J]. Ann Oncol, 2006,17(12): 1766-1771.
  • 5Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma [J]. Blood, 2006,108(7):2159-2164.
  • 6Richardson PG,Barlogie B,Berenson J,et al.A phase 2 study of bortezomib in relapsed,refractory myeloma.N Engl J Med,2003,348:2609-2617.
  • 7Jagannath S,Barlogie B,Berenson J,et al.A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.Br J Haematol,2004,127:165-172.
  • 8Richardson PG,Sonneveld P,Schuster M,et al.Extended follow-up of a phase 3 trial in relapsed multiple myeloma:final time-to-event results of the APEX trial.Blood,2007,110:3557-3560.
  • 9Richardson PG,Hideshima T,Mitsiades C,et al.The emerging role of novel therapies for the treatment of relapsed myeloma.J Natl Compr Canc Netw,2007,5:149-162.
  • 10Garcia-Sanz R,Gonzalez-Fraile MI,Sierra M,et al.The combination of thalidomide,cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma.Hematol J,2003,3:43-48.

共引文献12

同被引文献19

  • 1陈世伦,李敬东,刘霆,克晓燕,董菲,董陆佳,楼方定.第45届美国血液学年会纪要[J].中华内科杂志,2004,43(6):464-468. 被引量:20
  • 2李睿,陈燕.老年急性白血病的临床特点及免疫学表型的研究[J].中国实验血液学杂志,2006,14(6):1221-1226. 被引量:8
  • 3钱思轩,李建勇,沈云峰,蒋元强,陆化,吴汉新,徐卫,程蕴琳,盛瑞兰.CAG预激方案治疗老年人急性髓细胞白血病的临床观察[J].中华老年医学杂志,2007,26(4):248-250. 被引量:39
  • 4Lim ST,Levine AM. Angiogenesis and hematological malignancies[J].{H}HEMATOLOGY,2005.11-24.
  • 5张之南;沈悌.血液病诊断及疗效标准[M]北京:科学出版社,2007106.
  • 6周际昌.实用肿瘤内科学[M]北京:人民卫生出版社,199923.
  • 7Lee CY,Tien HF,Hu CY. Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia[J].{H}British Journal of Cancer,2007.877-882.
  • 8Vasvari GP,Dyckhoff G,Kashfi F. Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo[J].{H}International Journal of Cancer,2007.1697-1704.
  • 9Haslett PA,Roche P,Butlin CR. Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation[J].{H}Journal of Infectious Diseases,2005.2045-2053.
  • 10Steins MB,Padro T,Bieker R. Efficacy and safety of thalidomide in patients with acute myeloid leukemia[J].{H}Blood,2002.834-839.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部